Mind Medicine (MindMed) Inc. (MNMD) News

Mind Medicine (MindMed) Inc. (MNMD): $0.68

-0.02 (-2.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MNMD to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter MNMD News Items

MNMD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MNMD News Highlights

  • MNMD's 30 day story count now stands at 17.
  • Over the past 16 days, MNMD's stories per day has been in a clear downtrend, falling by about 1.20 per 4 days.
  • The most mentioned tickers in articles about MNMD are NEO, CHGG and HOG.

Latest MNMD News From Around the Web

Below are the latest news stories about Mind Medicine (MindMed) Inc that investors may wish to consider to help them evaluate MNMD as an investment opportunity.

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today that all the Company's issued and outstanding multiple voting shares (the "Multiple Voting Shares") will undergo a mandatory conversion into subordinate voting shares (the "Subordinate Voting Shares") (the "Conversion"), in accordance with the Company's Articles. The Co

Yahoo | February 23, 2022

Psychedelic Stock Gainers And Losers From February 15, 2022 | Benzinga

GAINERS: Mind Medicine (NASDAQ:

Benzinga | February 15, 2022

Why Shares of Mind Medicine Jumped 13.4% on Wednesday

The clinical-stage biopharmaceutical company benefited from an increased interest in companies working on psychedelic therapies.

The Motley Fool | February 9, 2022

FDA Greenlight Sets the Stage for Upside With Mind Medicine

Few catalysts can move healthcare stocks like a regulatory clearance can - and MNMD stock could be 2022's top psychedelics-sector investment.

David Moadel on InvestorPlace | February 8, 2022

Thinking about buying stock in Velodyne Lidar, Chegg, Louisiana-Pacific Corp, Harley-Davidson, or Mind Medicine?

NEW YORK , Feb. 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VLDR, CHGG, LPX, HOG, and MNMD. … Full story available on Benzinga.com

Benzinga | February 8, 2022

IIROC Trade Resumption - MMED

TORONTO , Feb. 7, 2022 /CNW/ - Trading resumes in: Company: MIND MEDICINE (MINDMED) INC. NEO Exchange Symbol: MMED All Issues: No Resumption (ET): 3:26:19 PM IIROC can make Full story available on Benzinga.com

Benzinga | February 7, 2022

IIROC Trading Halt - MMED

The following issues have been halted by IIROC:

Yahoo | February 7, 2022

MindMed gets FDA OK to start trial for pharmacological LSD in anxiety disorder

Mind Medicine (MNMD) is trading ~7% higher in the pre-market after announcing that the FDA cleared its Investigational New Drug ((IND)) application, allowing the company to start a Phase…

Seeking Alpha | January 25, 2022

Busey Wealth Management Buys Broadcom Inc, Canadian Pacific Railway, Globe Life Inc, Sells ...

Investment company Busey Wealth Management (Current Portfolio) buys Broadcom Inc, Canadian Pacific Railway, Globe Life Inc, BTC iShares U.S.

Yahoo | January 25, 2022

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared MindMed's Investigational New Drug (IND) application, allowing the Company's Phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder (GAD) to proceed.

Yahoo | January 25, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5625 seconds.